This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Close
Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • Avastin® (bevacizumab)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼(pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozlytrek▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Immunology
      • RoACTEMRA® (tocilizumab)
      • Haematology
      • Gazyvaro® (obinutuzumab)
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib)
      • Avastin® (bevacizumab)
      • Esbriet® (pirfenidone)
      • GAZYVARO® (obinutuzumab)
      • HEMLIBRA®▼(emicizumab)
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab) GB
      • OCREVUS®▼ (ocrelizumab) NI
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin)
      • RoACTEMRA® (tocilizumab) RA/GCA
      • RoACTEMRA® (tocilizumab) pJIA/sJIA
      • RoACTEMRA® (tocilizumab) CRS
      • Rozlytrek® ▼(entrectinib)
      • TECENTRIQ®▼ (atezolizumab) 1200mg - Hepatocellular Carcinoma [Great Britain]
      • TECENTRIQ®▼ (atezolizumab) 1200mg - Hepatocellular Carcinoma [Northern Ireland]
      • TECENTRIQ®▼ (atezolizumab) 1200mg - Lung Cancer [Great Britain]
      • TECENTRIQ®▼ (atezolizumab) 840mg - Lung Cancer [Great Britain]
      • TECENTRIQ®▼ (atezolizumab) 1200mg - Lung Cancer [Northern Ireland]
      • TECENTRIQ®▼ (atezolizumab) 840mg - Lung Cancer [Northern Ireland]
      • TECENTRIQ®▼ (atezolizumab) 840mg - Triple Negative Breast Cancer [Great Britain]
      • TECENTRIQ®▼ (atezolizumab) 840mg - Triple Negative Breast Cancer [Northern Ireland]
      • TECENTRIQ®▼ (atezolizumab) 1200mg - Urothelial Carcinoma [Great Britain]
      • TECENTRIQ®▼ (atezolizumab) 840mg - Urothelial Carcinoma [Great Britain]
      • TECENTRIQ®▼ (atezolizumab) 1200mg - Urothelial Carcinoma [Northern Ireland]
      • TECENTRIQ®▼ (atezolizumab) 840mg - Urothelial Carcinoma [Northern Ireland]
    • Adverse Events Reporting
      Adverse Events Reporting Overview
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.

    Breast Cancer


    You are here:

    1. Therapy Areas
    2. Oncology
    3. Breast Cancer

    ASCO 2020

    Learn more about the key breast cancer data highlights presented at the virtual ASCO 2020 annual meeting.

    More

    All data included on these pages for Roche products fall within the relevant product licence. However, these pages may also contain data for non-Roche molecules that are not yet licensed in the UK, and non-Roche medicines used outside of their licensed indications. Should you require further information on a molecule that is not produced by Roche Products Ltd., please contact the relevant manufacturer.

     

    M-GB-00001551

    Date of preparation: September 2020

     

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2021 Roche Products Limited
    • 19.01.2021
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. ▼Additional monitoring: Medicinal products associated with this symbol are subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. For biological medicines, healthcare professionals should report adverse reactions by brand name and batch number. This is a promotional website intended for HCPs, designed, built and funded by Roche Products Ltd. Commentary and other materials, including external links, posted on this site are not intended to amount to advice on which reliance should be placed. We therefore disclaim all liability and responsibility arising from any reliance placed on such materials by any visitor to our site, or by anyone who may be informed of any of its contents. M-GB-00002434 Date of Preparation January 2021.